share_log

Vertex Pharmaceuticals | 8-K: Current report

SEC announcement ·  Apr 11 07:14
Summary by Moomoo AI
On April 10, 2024, Vertex Pharmaceuticals Incorporated (Vertex) announced the entry into a Merger Agreement with Alpine Immune Sciences, Inc. The agreement stipulates that Vertex's subsidiary, Adams Merger Sub, Inc., will initiate a cash tender offer to acquire all outstanding shares of Alpine Immune Sciences at $65.00 per share. The offer is contingent upon several conditions, including the majority of Alpine's shares being tendered, regulatory approvals, and other customary conditions. The tender offer is set to commence within 10 business days from the date of the agreement and will expire 20 business days after its commencement, unless extended. Following the completion of the offer, Alpine Immune Sciences will become a wholly owned subsidiary of Vertex. In connection with the Merger Agreement, significant shareholders...Show More
On April 10, 2024, Vertex Pharmaceuticals Incorporated (Vertex) announced the entry into a Merger Agreement with Alpine Immune Sciences, Inc. The agreement stipulates that Vertex's subsidiary, Adams Merger Sub, Inc., will initiate a cash tender offer to acquire all outstanding shares of Alpine Immune Sciences at $65.00 per share. The offer is contingent upon several conditions, including the majority of Alpine's shares being tendered, regulatory approvals, and other customary conditions. The tender offer is set to commence within 10 business days from the date of the agreement and will expire 20 business days after its commencement, unless extended. Following the completion of the offer, Alpine Immune Sciences will become a wholly owned subsidiary of Vertex. In connection with the Merger Agreement, significant shareholders of Alpine Immune Sciences, holding approximately 25.5% of the outstanding shares, have entered into Tender and Support Agreements, committing to tender their shares. The merger is not subject to a financing condition and is expected to be completed by April 10, 2025, unless terminated under certain circumstances, which may require Alpine Immune Sciences to pay Vertex a termination fee of $173 million. The announcement was made alongside a joint press release issued by both companies.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more